Dabur India Limited

• Dabur is a leading consumer goods company in India with a turnover of Rs. 2834.11 Crore (FY09)
• 3 major strategic business units (SBU) – Consumer Care Division (CCD), Consumer Health Division (CHD) and International Business Division (IBD)
• 3 Subsidiary Group companies – Dabur International, Fem Care Pharma and newu and 8 step down subsidiaries: Dabur Nepal Pvt Ltd (Nepal), Dabur Egypt Ltd (Egypt), Asian Consumer Care (Bangladesh), Asian Consumer Care (Pakistan), African Consumer Care (Nigeria), Naturelle LLC (Ras Al Khaimah-UAE), Weikfield International (UAE) and Jaquline Inc. (USA).
• 17 ultra-modern manufacturing units spread around the globe
• Products marketed in over 60 countries
• Wide and deep market penetration with 50 C&F agents, more than 5000 distributors and over 2.8 million retail outlets all over India
• Consumer Care Division (CCD) adresses consumer needs across the entire FMCG spectrum through four distinct business portfolios of Personal Care, Health Care, Home Care & Foods
• Master brands:
  • Dabur – Ayurvedic healthcare products
  • Vatika – Premium hair care
  • Hajmola – Tasty digestives
  • Réal – Fruit juices & beverages
  • Fem – Fairness bleaches & skin care products
• 9 Billion-Rupee brands: Dabur Amla, Dabur Chyawanprash, Vatika, Réal, Dabur Red Toothpaste, Dabur Lal Dant Manjan, Babool, Hajmola and Dabur Honey
• Strategic positioning of Honey as food product, leading to market leadership (over 75%) in branded honey market
• Dabur Chyawanprash the largest selling Ayurvedic medicine with over 65% market share.
• Vatika Shampoo has been the fastest selling shampoo brand in India for three years in a row
• Hajmola tablets in command with 75% market share of digestive tablets category. About 2.5 crore Hajmola tablets are consumed in India every day
• Leader in herbal digestives with 90% market share
• Consumer Health Division (CHD) offers a range of classical Ayurvedic medicines and Ayurvedic OTC products that deliver the age-old benefits of Ayurveda in modern ready-to-use formats
• Has more than 300 products sold through prescriptions as well as over the counter
• Major categories in traditional formulations include:
  • Asav Arishtas
  • Ras Rasayanas
  • Churnas
  • Medicated Oils
• Proprietary Ayurvedic medicines developed by Dabur include:
  • Nature Care Isabgol
  • Madhuvaani
  • Trifgol
• Division also works for promotion of Ayurveda through organised community of traditional practitioners and developing fresh batches of students
• International Business Division (IBD) caters to the health and personal care needs of customers across different international markets, spanning the Middle East, North & West Africa, EU and the US with its brands Dabur & Vatika
• Growing at a CAGR of 33% in the last 6 years and contributes to about 20% of total sales
• Leveraging the ‘Natural’ preference among local consumers to increase share in perosnal care categories
• Focus markets:
  • GCC
  • Egypt
  • Nigeria
  • Bangladesh
  • Nepal
  • US

• 1884 – Established by Dr. S K Burman at Kolkata
• 1896 – First production unit established at Garhia
• 1919 – Early 1900s – Production of Ayurvedic medicines
• Dabur identifies nature-based Ayurvedic medicines as its area of specialisation. It is the first Company to provide health care through scientifically tested and automated production of formulations based on our traditional science.
• 1930 – Automation and upgradation of Ayurvedic products manufacturing initiated
• 1936 – Dabur (Dr. S K Burman) Pvt. Ltd. Incorporated
• 1940 – Dabur introduces Indian consumers to personal care through Ayurveda, with the launch of Dabur Amla Hair Oil.
• 1949 - Widening the popularity and usage of traditional Ayurvedic products continues. The ancient restorative Chyawanprash is launched in packaged form, and becomes the first branded Chyawanprash in India.
• 1957 – Computerisation of operations initiated
• 1970 - Addressing rural markets where homemade oral care is more popular than multinational brands, Dabur introduces ‘Lal Dant Manjan’. With this a conveniently packaged herbal toothpowder is made available at affordable costs to the masses.
• 1972 – Shifts base to Delhi from Calcutta
• 1978 – Dabur continues to make innovative products based on traditional formulations that can provide holistic care in our daily life. An Ayurvedic medicine used as a digestive aid is branded and launched as the popular Hajmola tablet.
• 1979 – Dabur Research Foundation set up
• 1979 – Commercial production starts at Sahibabad, the most modern herbal medicines plant at that time
• 1984 – Dabur completes 100 years
• 1988 – Launches pharmaceutical medicines
• 1989 – The Ayurvedic digestive formulation is converted into a children’s fun product with the launch of Hajmola Candy. In an innovative move, a curative product is converted to a confectionary item for wider usage.
• 1994 – Comes out with first public issue
• 1994 – Enters oncology segment
• 1994 – Dabur establishes its leadership in health care as one of only two companies worldwide to launch the anti-cancer drug Intaxel (Paclitaxel). Dabur Research Foundation develops an eco-friendly process to extract the drug from its plant source
• 1996 – Dabur captures the imagination of young Indian consumers with the launch of Real Fruit Juices – a new concept in the Indian foods market. The first local brand of 100% pure natural fruit juices made to international standards, Real becomes the fastest growing and largest selling brand in the country.
• 1998 – Burman family hands over management of the company to professionals
• 2000 – Dabur establishes its market leadership status by staging a turnover of Rs.1,000 crores.
• 2001 – With the setting up of Dabur Oncology’s sterile cytotoxic facility, the Company gains entry into the highly specialised area of cancer therapy. The state-of-the-art plant and laboratory in the UK have approval from the MCA of UK. They follow FDA guidelines for production of drugs specifically for European and American markets.
• 2002 – Dabur record sales of Rs 1163.19 crore on a net profit of Rs 64.4 crore
• 2003 – Dabur India approved the demerger of its pharmaceuticals business from the FMCG business into a separate company as part of plans to provider greater focus to both the businesses. With this, Dabur India now largely comprises of the FMCG business that include personal care products, healthcare products and Ayurvedic Specialities, while the Pharmaceuticals business would include Allopathic, Oncology formulations and Bulk Drugs. Dabur Oncology Plc, a subsidiary of Dabur India, would also be part of the Pharmaceutical business.
• 2005 – As part of its inorganic growth strategy, Dabur India acquires Balsara’s Hygiene and Home products businesses, a leading provider of Oral Care and Household Care products in the Indian market, in a Rs 143-crore all-cash deal.
• 2005 – Dabur India announced issue of 1:1 Bonus share to the shareholders of the company, i.e. one share for every one share held. The Board also proposed an increase in the authorized share capital of the company from existing Rs 50 crore to Rs 125 crore.
• 2006 – Dabur India crosses the $2-billion mark in market capitalisation. The company also adopted US GAAP in line with its commitment to follow global best practices and adopt highest standards of transparency and governance.
• 2006 – Moving forward on the inorganic growth path, Dabur India decides to raise up to $200 million from the international market through Bonds, FCCBs, GDR, ADR, QIPs or any other securities.The capital raised will be used to fund Dabur’s aggressive growth ambitions and acquisition plans in India and abroad.
• 2007 – Dabur India announced its foray into the organised retail business through a wholly-owned subsidiary, H&B Stores Ltd. Dabur will invest Rs 140 crores by 2010 to establish its presence in the retail market in India with a chain of stores on the Health & Beauty format.
• 2007 – Dabur India decides to merge its wholly-owned subsidiary Dabur Foods Limited with itself to extract synergies and unlock operational efficiencies. The integration will also help Dabur sharpen focus on the high growth business of foods and beverages, and enter newer product categories in this space.
• 2008 – Dabur India acquires Fem Care Pharma, a leading player in the women’s skin care market. Besides an entry into the high-growth skin care market with an established brand name FEM, this transaction also offers Dabur a strong platform to enter newer product categories and markets.
• 2009 – Dabur Red Toothpaste becomes the Dabur’s ninth Billion Rupee brand. Dabur Red Toothpaste crosses the billion rupee turnover mark within five years of its launch.